Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Company Limited a biopharmaceutical company engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities and reformulated products with a therapeutic focus on oncology neurodegeneration ophthalmology dermatology and Immunology. The company offers Elepsia a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition it is developing SDN-037 a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138) which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive human epidermal receptor 2 negative and metastatic breast cancer which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet to develop an S1P receptor 1 agonist for autoimmune disorders. The company was incorporated in 2006 and is based in Mumbai India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited.